Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (17,8 Mio. €): Integriertes IMMUnoprofiling großer adaptiver CANcer-Patientenkohorten Hor 01.03.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Integriertes IMMUnoprofiling großer adaptiver CANcer-Patientenkohorten

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.


Geförderte Unternehmen:

Firmenname Förderungssumme
Abbvie Inc. 0,00 €
Association Hospitaliere de Bruxelles-Centre Hospitalier Universitaire Jules Bordet 350.000 €
Astrazeneca UK Ltd. 0,00 €
Bayer AG 0,00 €
Celsius Therapeutics Inc. 0,00 €
Centre de Lutte Contre le Cancer Leon Berard 200.000 €
Centre Hospitalier Universitaire Vaudois 2.202.543 €
Charite - Universitaetsmedizin Berlin 20.000 €
Cliniques Universitaires Saint-LUC ASBL 30.000 €
Consorcio para La Explotacion del Centro Nacional de Analisis Genomico 115.673 €
De Duve Institute Aisbl 0,00 €
Eli Lilly and Company Ltd. 0,00 €
Forum des Patients Europeens 210.000 €
Fundacio Centre de Regulacio Genomica 138.268 €
Glaxosmithkline Research & Development Ltd. 0,00 €
Institut Curie 510.000 €
Institut de Recherche Pierre Fabre 0,00 €
Institut de Recherches Internationales Servier 0,00 €
Institut Gustave Roussy 233.784 €
Institut National de la Sante et de la Recherche Medicale 448.320 €
Institut Servier de Medecine Translationnelle 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Katholieke Universiteit Leuven 1.712.880 €
King's College London 765.066 €
Ligue Nationale Contre le Cancer 40.780 €
Luxembourg Institute OF Health 2.807.976 €
Merck KGaA 0,00 €
Novigenix SA 0,00 €
Organisation Europeenne Pour la Recherche et le Traitement du Cancer Aisbl 5.257.790 €
Owkin France 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
SIB Swiss Institute OF Bioinformatics 1.773.000 €
The University of Birmingham 10.000,00 €
Universitat Zurich 728.701 €
Universite Paris Cite 79.220 €
Uniwersytet Warszawski 95.999 €
Weizmann Institute OF Science 100.000 €

Quelle: https://cordis.europa.eu/project/id/821558

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.